Browse News
Filter News
Found 636,409 articles
-
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
-
Convalescent plasma as a treatment for COVID-19 infections has demonstrated mixed results at best in terms of efficacy, and a recent trial in Argentina provides additional fuel to that conversation.
-
Days after Purdue Pharma reached a combined $8.4 billion criminal and civil settlement with the U.S. Department of Justice, the OxyContin drugmaker pleaded guilty to three criminal charges to resolve its role in the ongoing opioid crisis in the United States.
-
Guardant Health is taking Roche-owned Foundation Medicine to court over a patent dispute for their liquid biopsy technology, further heating up the rivalry between the two cancer detection companies.
-
MediciNova announced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects.
-
There has been a high level of movement in COVID-19 vaccine news this week, with Pfizer and BioNTech, Moderna, and AstraZeneca and the University of Oxford all having positive clinical trial announcements. Here’s some follow-up news.
-
Biopharma Money on the Move: November 18-24
11/25/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Preclinical contract research organization (CRO) Selvita has entered into a deal with Galapagos to acquire its inflammation-, fibrosis- and anti-infectives-focused CRO Fidelta.
-
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
-
In the cleanroom environment specifically, the benefits of automation are more than meets the microscope.
-
Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured on Multiple Television News Outlets
11/25/2020
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, reports that its lead drug candidate, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes, has been featured on multiple television news outlets.
-
CaptiGen, LLC Announces Enhanced Covid-19 Testing
11/25/2020
CaptiGen, LLC is pleased to announce the development of CaptiSwab, sterile, individually wrapped, knitted textile swabs for the collection of clinical samples for microbial detection through standard culture, RT-PCR, and next-generation sequencing (NGS).
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11/25/2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan
-
PostEra and NeuroLucent collaborate on identifying small-molecule therapeutics for Alzheimer's disease
11/25/2020
PostEra, a biotechnology company offering medicinal chemistry powered by machine learning, today announced a collaboration with NeuroLucent, a Chicago-based company focused on developing novel treatments for Alzheimer's disease and other dementias.
-
Logmore Launches First Logistics Monitor Designed for COVID-19 Vaccine Delivery
11/25/2020
Supply chain analytics solution provider Logmore has announced the launch of its latest product. Logmore Dry Ice, a high-spec version of Logmore’s original data recorder, has been adapted for cold and sub-zero conditions
-
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
11/25/2020
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clinical trial ("Study 101").
-
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
11/25/2020
Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.
-
Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
11/25/2020
Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin® (bevacizumab), to EMA.
-
Acerus Announces Completion of Over-Subscribed Rights Offering
11/25/2020
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce the completion of its rights offering (the “Rights Offering”), which expired at 5:00 pm (EST) on November 24, 2020.
-
Partnership commits $24.5M to support innovation in Canadian cancer services
11/25/2020
The Canadian Partnership Against Cancer is working with partners across Canada to innovate cancer care, with a focus on improving access to world class cancer screening services for underserviced populations in the wake of a pandemic that's changed the face of health care TORONTO , Nov. 25, 2020 /CNW/ - The Canadian Partnership Against Cancer (the Partnership) is i